DeSci · explained
Why this initiative exists
Early intervention in psychosis is scientifically important and hard to fund through usual biotech channels. We are building a clear, honest public home for the science — and designing a proposed private way for eligible investors to support a defined CHR-P programme without taking over the company or the clinic.
Proposed arrangements — not live financing. This page explains intent and design. There is no investment button, payment flow, wallet connection, or token sale on this website.
The problem we are trying to solve
People who meet clinical high-risk criteria can experience distressing symptoms long before any diagnosis of schizophrenia. Research that tests whether carefully designed interventions can help earlier is valuable — and often difficult to finance with conventional venture timelines and endpoint expectations.
Working idea: bring together specialist life-sciences capital and newer constituencies (including crypto-native family offices and DeSci-aware investors) around a ring-fenced programme, with transparent use of proceeds and pharmaceutical-grade governance.
How programme funding could work Proposed
- Dedicated vehicle — a separate programme entity for CHR-P economics, not a sale of NWPharmaTech parent shares.
- Private placement — legally eligible investors only (accredited / professional / institutional as the chosen laws require), with an enforceable investor register.
- Defined use of proceeds — catalytic capital aimed at a graded scientific package (working fundraising target ~US$10 million until a bottoms-up budget is locked).
- Conventional documents first — contracts and the register are the funding path; a permissioned on-chain representation of that register is optional later, not required to raise.
- No public market theatre — no decentralised exchange, no retail token sale, no “invest now” on this site in the current design.
What “community participation” means here
We use “community” carefully. Different audiences have different roles:
- Patients, families, clinicians, researchers, journalists — welcome on this informational site for science context, FAQ, and contact. This is not a diagnosis service, enrolment portal, or fundraising funnel for the public.
- Eligible private investors — if financing proceeds, participation would mean holding expressly granted programme economic rights under private documents — not owning the medicine, patient data, or NWPT as a company.
- Not on the table: token votes on dose, endpoints, eligibility, safety, or regulatory filings; community ownership of the drug; public crowdfunding of the trial through this website.
Which decisions remain with NWPharmaTech
Established policy:
- Clinical protocol, dose, endpoints, eligibility, safety monitoring, and regulatory submissions
- Sponsor accountability to patients, investigators, ethics committees, and regulators
- Core intellectual property and partnering flexibility for the parent company, except where a Board-approved document expressly grants a narrow right
Investors would not receive a clinical veto or a parent-board seat by default. Any observer or information rights would be vehicle-level and contractual — never a substitute for medical judgement.
What we are not claiming
- That psychosis prevention is already proven for our candidate
- That a DAO legal entity already exists or that “NW PharmaTech DAO” is a live investment product
- That financing is open, that ~US$10 million is raised, or that you can subscribe here
- That Molecule, BIO, or any other platform is a contracted partner (paper assessment only; no outreach without separate approval)